Thaller, Mark http://orcid.org/0000-0001-7772-2157
Homer, Victoria http://orcid.org/0000-0003-3639-7874
Sassani, Matilde http://orcid.org/0000-0002-0384-7296
Mollan, Susan P. http://orcid.org/0000-0002-6314-4437
Sinclair, Alexandra J. http://orcid.org/0000-0003-2777-5132
Funding for this research was provided by:
RCUK | Medical Research Council (MR/KO15184/1)
Sir Jules Thorn Charitable Trust (n/a)
Article History
Received: 20 September 2022
Revised: 6 April 2023
Accepted: 26 April 2023
First Online: 24 May 2023
Competing interests
: MT reports no conflicts. VH reports no conflicts. MS reports no conflicts SPM reports consultancy fees (Invex Therapeutics); advisory board fees (Invex therapeutics; Gensight) and speaker fees (Heidelberg engineering; Chugai-Roche Ltd; Allergan; Santen; Teva UK; Chiesi; and Santhera). AJS reports personal fees from Invex therapeutics during the conduct of the study as well as share option and shareholdings, speaker fees (Novartis; Allergan; Teva UK) and consulting fees (Allergan; Chiesi; Novartis; Lundbeck).
: The study was ethically approved by National Health Service National Research Ethics Committee (14/LO/1208), IIH:LIFE study. The human study has been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.